In the News |
October 28, 2024
With $92M, Kivu sets out to make ‘kinder, gentler’ ADCs

“The startup, which is backed by Novo Holdings and a handful of other venture firms, is the latest to capitalize on interest in the targeted cancer drugs.”

Gwendolyn Wu, Biopharma Dive